Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial

In older adults, induction with six cycles of FOLFIRI-A plus maintenance with 5-FU/LV-A was non-inferior to FOLFIRI-A until progression. Severe asthenia, SAEs, and treatment-related SAEs were reduced with 5-FU/LV-A maintenance.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2024-11-27
DOI
https://doi.org/10.1016/j.esmoop.2024.103986
Citations
1
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.28

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial

Ana Fernández Montés, Cristina Grávalos, C. López-López, Tomás Fernández‐Rodríguez et al.
1 citations
ESMO Open
Colorectal Cancer Treatments and Studies
0.28
article

Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial

Ana Fernández Montés, Cristina Grávalos, C. López-López, Tomás Fernández‐Rodríguez, Marta Guix, Alfonso Yubero, Élena Elez, I Macías, Guillermo Quintero, David Páez, J. Sastre, Encarnación González‐Flores, Enrique Aranda, Beatriz Paredes, Antonieta Salud, Pilar García‐Alfonso, J.J. Reina, James F. Mowbray, María Auxiliadora Gómez‐España, Javier Soto‐Alsar
article en
1 citations

Abstract

In older adults, induction with six cycles of FOLFIRI-A plus maintenance with 5-FU/LV-A was non-inferior to FOLFIRI-A until progression. Severe asthenia, SAEs, and treatment-related SAEs were reduced with 5-FU/LV-A maintenance.

ESMO OpenVol. 9(12)
Hebron University (PS), Instituto de Salud Carlos III (ES), Hospital de Sant Pau (ES), Hospital Universitari Arnau de Vilanova (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital Clínico San Carlos (ES), Hospital Son Llatzer (ES), Hospital Universitario Virgen Macarena (ES), Instituto Maimónides de Investigación Biomédica de Córdoba (ES), Hospital Universitario 12 De Octubre (ES), Vall d'Hebron Institut de Recerca (ES), Instituto de Investigación Marqués de Valdecilla (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital Universitario Reina Sofía (ES), Hospital de Sabadell (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Del Mar (ES), Hospital Clínico Universitario Lozano Blesa (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Universitario Lucus Augusti (ES), Hospital Universitario Virgen del Rocío (ES), Instituto de Investigación Biomédica de A Coruña (ES), Complejo Hospitalario de Ourense (ES), University of Córdoba (ES)
Sanofi
Good health and well-being
Openalex Percentile: Top 34%
Colorectal Cancer Treatments and Studies
0.28
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.